Additionally, the EXTREME trial assessed the combination of cetuximab, another EGFR-targeting agent, with chemotherapy for advanced HNSCC, improving survival rates in patients with EGFR overexpression (50). Here, EGFR is linked to head and neck squamous cell carcinoma.